Bintie Biotech Secures Over RMB 100 Million Series A Financing to Advance KRAS-Targeted TCR-T Cell Therapy

Oct 31, 2023 09:58 CST Updated 09:59

Immuxell Biotech

Developer of Immune Cell Therapeutic Drugs

Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any issues are welcome. This article is only an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if applicable). This article does not constitute any investment advice.

Recently, ImmuXell Biotech LtD. (referred to as "ImmuXell Biotech") announced the completionOver 100 Million YuanARound FinancingThis round of financing was led by SDIC Venture Capital Co., Ltd., with participation from Guangzhou Huangpu Biomedical Industry Investment Fund Management Co., Ltd., Yuanxi Haihe (Tianjin) Biomedical Industry Fund Partnership (Limited Partnership), and others, supporting ImmuXell Biotech in advancing new technology research and development, commercial production implementation, and international business strategic layout.The funds raised in this round will be used to accelerate the advancement ofKRAS G12VNovel MutationTCR-TCell Therapy ProductsApplication for registration of clinical trials, as well as product development and international cooperation for multiple subsequent innovative pipelines.

SDIC Venture Capital, Guangzhou Huangpu Biomedical Industry Investment Fund Management Co., Ltd., and Yuanxi Haihe (Tianjin) Biomedical Industry Fund Partnership (Limited Partnership) have deep industry backgrounds and extensive investment experience in the biopharmaceutical field. In the future, ImmuXell Biotech will leverage the resource advantages of its new shareholders to accelerate the company's growth and internationalization process. At the same time, ImmuXell Biotech will continue to strengthen platform construction and pipeline advancement, providing patients with more efficient and personalized cell therapy services.

Regarding this investment, SDIC Venture Capital Co., Ltd., Guangzhou Huangpu Biomedical Industry Investment Fund Management Co., Ltd., and Yuanxi Haihe (Tianjin) Biomedical Industry Fund Partnership (Limited Partnership) all expressed that they are optimistic about ImmuXell Biotech's innovation capabilities and development potential in the field of immune cell therapy. They hope this round of funding will promote ImmuXell Biotech’s treatment for relapsed and refractory solid tumors.TCR-TThe R&D Progress of Innovative Drugs. This investment is another significant layout by SDIC Venture Capital Co., Ltd., Guangzhou Huangpu Biomedical Industry Investment Fund Management Co., Ltd., and Yuanxi Haihe (Tianjin) Biomedical Industry Fund Partnership (Limited Partnership) in the life sciences and healthcare sector. In the future, they will continue to actively seek out and support life sciences and healthcare projects with innovation capabilities and market potential, jointly promoting the rapid development of China's life sciences and healthcare industry.

About ImmuXell Biotech

ImmuXell Biotech was founded in2021Year1Month, Registered Capital2000Located in the Kangqiao Industrial Zone of Shanghai's Zhangjiang Science City, ImmuXell Biotech is a clinical-stage biopharmaceutical innovation company focused on the research, development, and production of breakthrough immunotherapy drugs. Its main product is a novel immune cell preparation targeting solid tumors.

Dr. Hu Hongming, the founder of the company, has深耕多年 in the field of tumor immunology and possesses extensive experience in basic and clinical research of tumor immunology as well as translational medicine. Several immunotherapy drugs he originally developed have entered the clinical trial stage. Building on this foundation, ImmuXell Biotech has developed multiple product pipelines with independent intellectual property rights. Among them, 针对KRASMutatedTCR-TCell therapy products have been completed.TCRScreening, in vitro functional identification, in vivo efficacy experiments, and investigator-initiated clinical trials for advanced pancreatic ductal adenocarcinoma have been completed across multiple clinical centers (IIT), has currently enteredINDPreparation phase for submission. In addition, significant breakthroughs have been made in ImmuXell Biotech's other product pipelines, including those that can serve as allogeneic cell therapy products.TCR-NKProducts, as well as those that can be mass-produced and openly supplied.TCRFusion protein products.

Since its establishment, ImmuXell Biotech has achieved rapid development in platform construction, pipeline setup, and product layout. The future goal is to identify shared gene mutations and tumor neoantigens, and to develop a series of treatments for recurrent and refractory malignant tumors such as pancreatic cancer.TCRProducts, combining personalized and universal cell therapy products to enhance the effectiveness and accessibility of cell therapies, benefiting a broader patient population.

▲ImmuXell Biotech Laboratory

Source: ImmuXell Biotech